Antiviral medications for herpes simplex virus
Pro Research Analysisby 
Searched over 200M research papers
Antiviral Medications for Herpes Simplex Virus: Current Options and Emerging Therapies
Standard Antiviral Drugs for Herpes Simplex Virus (HSV)
The mainstay of treatment for herpes simplex virus infections, including both HSV-1 and HSV-2, is antiviral chemotherapeutic agents. The most commonly used drugs are nucleoside analogs such as acyclovir, valacyclovir, penciclovir, and famciclovir. These medications are effective in reducing the severity and duration of outbreaks, but they do not eliminate the virus or prevent future recurrences. Acyclovir, in particular, is highly effective for both prevention and treatment, especially in immunocompromised patients, and is considered the top choice for preventing oral HSV infections, followed by valacyclovirSadowski2021Al-Zoobaee2020.
Drug Resistance and Alternative Therapies
Drug resistance, especially to acyclovir and related nucleoside analogs, is a growing concern, particularly among immunocompromised individuals. Resistance is most often due to mutations in the viral thymidine kinase (TK) gene, which is required for the activation of these drugs. When resistance occurs, alternative treatments such as foscarnet and cidofovir are used, as they do not rely on TK for their antiviral activity. However, these alternatives are more toxic and may also face resistance if the viral DNA polymerase is mutatedBurrel2020Morfin2003.
Combination and Novel Antiviral Approaches
Recent research has explored combination therapies to address drug resistance and improve efficacy. For example, combining acyclovir, cidofovir, and amenamevir (a newer drug targeting the helicase-primase complex) has shown additive antiviral effects against HSV-1 without significant drug-drug interactions, suggesting potential for multidrug regimens.
Additionally, new classes of antiviral agents are under investigation. These include small molecule inhibitors, biopharmaceuticals, natural products, gene editing, and oligonucleotide-based therapies. Some promising candidates are β-carboline derivatives, which have demonstrated the ability to inhibit both HSV-1 and HSV-2 by interfering with viral protein expression and replication at later stages of infection. Natural compounds like triptolide and peptide antivirals such as WL-1 (derived from human cathelicidin) have also shown antiviral activity against HSV-1 in laboratory studies, offering hope for new, less toxic treatment optionsAliabadi2022Guo2023.
Addressing Drug Resistance: New Strategies
To combat the challenge of drug resistance, researchers are developing drugs that target new viral components, such as the DNA helicase/primase complex, and exploring molecules with dual mechanisms, like Janus-type nucleosides, which can disrupt viral DNA synthesis more effectively. These strategies aim to provide alternatives for patients who do not respond to standard therapies and to reduce the emergence of resistant HSV strainsFrejborg2022Jiang2016.
Conclusion
Acyclovir and related nucleoside analogs remain the cornerstone of HSV treatment, but drug resistance and the inability to eradicate latent infection highlight the need for new therapies. Alternative drugs like foscarnet and cidofovir are available for resistant cases, though with higher toxicity. Ongoing research into combination therapies, novel small molecules, natural products, and peptide antivirals is expanding the arsenal against HSV, with the goal of more effective and safer treatments for all patient populationsGonzalez2018Greeley2020Frejborg2022+7 MORE.
Sources and full results
Most relevant research papers on this topic
DOI